LITS— Lite Strategy, Inc.

MaterialsBiotechnology$31M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$0-100.0%	$65.3M+33.8%	$48.8M+19.9%	$40.7M
Research and development	$3.9M-76.3%	$16.6M-68.4%	$52.5M-38.8%	$85.6M
General and administrative	$13.5M-41.9%	$23.3M-29.7%	$33.1M+8.5%	$30.5M
Impairment of long-lived assets	$0-100.0%	$10.9M	$0	—
Total operating expenses	$17.5M-65.6%	$50.8M-40.7%	$85.6M-26.3%	$116.2M
(Loss) income from operations	-$17.5M-220.0%	$14.5M+139.6%	-$36.8M+51.3%	-$75.5M
Interest and dividend income	$1.0M-68.7%	$3.3M-2.0%	$3.3M+1077.8%	$284K
Gain on disposition of a non-financial asset	$500K	$0	—	—
Other expense, net	-$16K+61.0%	-$41K-86.4%	-$22K-266.7%	-$6K
Total other income, net	$1.5M-53.3%	$3.2M-34.3%	$4.9M-76.6%	$21.0M
Net (loss) income	-$15.9M-189.7%	$17.8M+155.8%	-$31.8M+41.5%	-$54.5M
Basic	-$2K-189.5%	$3K+155.9%	-$5K+45.4%	-$9K
Diluted	-$2K-189.5%	$3K+155.9%	-$5K+52.2%	-$10K
Basic	$6.7M+0.0%	$6.7M+0.0%	$6.7M-94.6%	$124.5M
Diluted	$6.7M+0.0%	$6.7M+0.0%	$6.7M-94.7%	$125.1M
Revenue from customers
Revenue from collaboration agreements

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.